"Promising Alzheimer's Drug Donanemab Offers Hope for Patients"

Trial results of the Alzheimer's drug donanemab show it can slow cognitive decline by 35% in people with early or mild disease. However, the drug is not a cure and has potential risks, including brain swelling. Donanemab has been approved by the US FDA and the manufacturer has applied for approval in Australia. The drug's cost is significant, and its availability may be restricted to those who match the trial population. Early detection and treatment infrastructure need to be developed to facilitate timely diagnosis and treatment.